Sartorius Stedim Biotech S.A.

Total Valuation

Sartorius Stedim Biotech S.A. carries a market capitalization of 20.86B, placing it among publicly traded companies globally. Its enterprise value stands at 21.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sartorius Stedim Biotech S.A. currently has 97.29M shares outstanding.

Valuation Ratios

Sartorius Stedim Biotech S.A. trades at a trailing price-to-earnings ratio of 86.53. The price-to-sales ratio is 6.73, and the price-to-book ratio stands at 7.55.

Enterprise Valuation

On an enterprise value basis, Sartorius Stedim Biotech S.A. trades at an EV/EBITDA multiple of 48.00 and an EV/FCF ratio of 18.22. The EV/Sales ratio of 7.51 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 48.00 provides insight into valuation relative to core operating earnings.

Financial Position

Sartorius Stedim Biotech S.A. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 73.51, indicating elevated leverage, while an interest coverage ratio of 3.16 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Sartorius Stedim Biotech S.A. posts a return on equity of 8.93 and a return on invested capital of 5.13.

Taxes

Over the trailing twelve months, Sartorius Stedim Biotech S.A. has paid 57.80M in income taxes, reflecting an effective tax rate of 20.32.

Stock Price Statistics

Sartorius Stedim Biotech S.A.'s stock has declined approximately -10.44078% over the past 52 weeks. The 50-day moving average sits at 196.08, while the 200-day moving average is 216.16.

Income Statement

Over the trailing twelve months, Sartorius Stedim Biotech S.A. generated 2.90B in revenue and converted that into 225.20M in net income, yielding earnings per share of 2.31. EBITDA reached 453.10M, while operating income came in at 453.10M.

Balance Sheet

Sartorius Stedim Biotech S.A. holds 745.10M in cash and equivalents against 2.97B in total debt, resulting in a net debt position of 2.10B. Total book value stands at 2.58B, with working capital of 861.00M providing operational flexibility.

Cash Flow

Sartorius Stedim Biotech S.A. produced 788.10M in operating cash flow over the past twelve months. After subtracting -291.60M in capital expenditures, free cash flow totaled 496.50M - equivalent to 5.06 per share.

Margins

Sartorius Stedim Biotech S.A. operates with a gross margin of 44.63, reflecting its pricing power and cost economics. The operating margin of 15.64 and net profit margin of 7.78 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Sartorius Stedim Biotech S.A.'s most recent stock split took place on May 6, 2016 with a 1:6 split ratio.

Scores

Sartorius Stedim Biotech S.A. posts an Altman Z-Score of 5.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.